Business
Therma Bright Announces: Further Testing of TherOZap(TM) Technology at Inhibiting Zika and Other Mosquito Borne Diseases, Proposed Financings and Acquisition Update
Toronto, Ontario--(Newsfile Corp. - April 19, 2018) - Therma Bright Inc. (TSXV: THRM), (" The ...
About this update from Therma Bright Inc.
[{"type":"text","content":"Therma Bright Announces: Further Testing of TherOZap(TM) Technology at Inhibiting Zika and Other Mosquito Borne Diseases, Proposed Financings and Acquisition UpdateToronto, Ontario--(Newsfile Corp. - April 19, 2018) - Therma Bright Inc. (TSXV: THRM), (\"Therma Bright\" or the \"Company\"), a progressive medical device technology company, provides the following updates:Therma Bright to conduct further testing of TherOZap™ technology at inhibiting Zika and other mosquito borne diseasesTherma Bright announces that further to its press release on January 8, 2018 outlining results indicating effectiveness of its TherOZap™ technology in inhibiting the Zika virus, that the Company will continue testing of the TherOZap™ technology against the Zika virus and other mosquito borne diseases. After consultation with various research laboratories specialized in studying mosquito borne disease, Therma Bright intends to test the TherOZap™ technology against the Zika and Dengue viruses. According to the World Health Organization: \"Dengue effects a much larger percentage of the world population with about half of the world's population now at risk. Dengue is found in tropical and sub-tropical climates worldwide, mostly in urban and semi-urban areas. Severe dengue is a leading cause of serious illness and death among children in some Asian and Latin American countries.\"The Dengue, Zika and West Nile viruses are spread by the same mosquito which is known as the Aedes Aegypti mosquito. The Aedes Aegypti mosquito is known as a prolific daytime biter which often makes it harder for people to protect themselves after an infectious bite. Therma Bright intends to test its TherOZap™ technology and hopes to prove the technology will be effective as a second line of defense after someone has been bitten. Therma Bright looks forward to reporting back to shareholders in the near future as the next round of research begins. Mr. Rob Fia, CEO, commented:\"We are excited to continue testing our patent pending TherOZap™ technology to inhibit the Zika virus and now potentially the Dengue virus. We've learned a lot about the Zika virus through consultation with research groups and it is interesting to learn that the Zika and Dengue viruses may be susceptible to die-off with the use of our TherOZap™ technology.\"Equi...